No Data
Channel Therapeutics Corporation Comments on Vertex Pharmaceuticals' Phase 2 Data for NaV1.8 Inhibitor and Outlines NaV1.7 Therapeutic Approach
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
Express News | Channel Therapeutics Corp - Formulations Show Improvement Over Bupivacaine in Efficacy and Duration
Express News | Channel Therapeutics Corp - Achieves Endpoints in Pre-Clinical Pain Studies
Express News | Channel Therapeutics Announces Positive Efficacy Data for a Depot Formulation of a Nav1.7 Inhibitor in a Preclinical in Vivo Nerve Block Model
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
with the color comment... hey, you can add target to the list too
that mustache 
